To offset losses due to sale of its generic injectible finished dosage assets to Hospira for $400 million in late 2009 and to achieve double-digit growth , Orchid Chemicals and Pharmaceuticals has drawn up a growth formula.
Orchid will continue to be Hospira’s long-term supplier of API (actual pharmaceutical ingredients) for injectible dosage assets. The company will also serve generics majors in emerging markets as well as the US and Europe.
Orchid will market 10 products in oral Cephalosphorins segment and five in NPNC (non pencillin-non cephalosphorin) segment. It will create additional capacities to widen its base further in the US, Europe and Japan markets, said company sources.
The company will look to acquire more front-end marketing companies (including its products, people and infrastructure) to give additional push to its products directly in these markets. It will keep introducing niche products for niche markets.
The company has acquired US-based Karalex Pharma, a generics marketing company. In the medium-term, over three years. Orchid will launch more than 20 products under NPNC category in the US market.
Orchid is marketing 31 products through four major players such as Actavis, North Star, Stada and Avlogen.
